Calmodulin-sensitive adenylyl cyclases mediate AVP-dependent cAMP production and Cl- secretion by human autosomal dominant polycystic kidney cells

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 10, 2012, Pages

  Pinto, Cibele S ^a   Reif, Gail A ^a   Nivens, Emily ^a   White, Corey ^a   Wallace, Darren P ^a,b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

ADPKD; Calcium; cAMP; Fluid transport; Vasopressin

Indexed keywords

ADENYLATE CYCLASE; AQUAPORIN 2; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALMODULIN; CHLORIDE; CYCLIC AMP; MESSENGER RNA; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; VASOPRESSIN;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLUID TRANSPORT; GENE EXPRESSION; HUMAN; HUMAN TISSUE; KIDNEY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REGULATORY MECHANISM; SECRETION (PROCESS); SIGNAL TRANSDUCTION;

EID: 84869169071     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00692.2011     Document Type: Article

References (74)

1. Bastos AP, Onuchic LF. Molecular and cellular pathogenesis of autosomal dominant polycystic kidney disease. Braz J Med Biol Res 44: 606-617, 2011.
2. Bek MJ, Zheng S, Xu J, Yamaguchi I, Asico LD, Sun XG, Jose PA. Differential expression of adenylyl cyclases in the rat nephron. Kidney Int 60: 890-899, 2001.
3. Belibi FA, Wallace DP, Yamaguchi T, Christensen M, Reif G, Grantham JJ. The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 13: 2723-2729, 2002.
4. Blount MA. A timely characterization of vasopressin-sensitive adenylyl cyclase isoforms in the mouse inner medullary collecting duct. Am J Physiol Renal Physiol 298: F857-F858, 2010.
5. Brill SR, Ross KE, Davidow CJ, Ye M, Grantham JJ, Caplan MJ. Immunolocalization of ion transport proteins in human autosomal dominant polycystic kidney epithelial cells. Proc Natl Acad Sci USA 93: 10206-10211, 1996.
6. 2+-inhibitable adenylyl cyclases along the renal tubule. Functional consequences for regulation of the cAMP content. J Biol Chem 271: 19264-19271, 1996.
7. Chien CL, Wu YS, Lai HL, Chen YH, Jiang ST, Shih CM, Lin SS, Chang C, Chern Y. Impaired water reabsorption in mice deficient in the type VI adenylyl cyclase (AC6). FEBS Lett 584: 2883-2890, 2010.
8. Cooper DM. Compartmentalization of adenylate cyclase and cAMP signalling. Biochem Soc Trans 33: 1319-1322, 2005.
9. Cooper DM. Regulation and organization of adenylyl cyclases and cAMP. Biochem J 375: 517-529, 2003.
10. Cooper DM, Hoffman W, Wheat N, Lee HY. Duration of effects on clinical parameters and referred hyperalgesia in rats after abdominal surgery and multiple doses of analgesic. Comp Med 55: 344-353, 2005.
11. Danielsen H, Pedersen EB, Nielsen AH, Herlevsen P, Kornerup HJ, Posborg V. Expansion of extracellular volume in early polycystic kidney disease. Acta Med Scand 219: 399-405, 1986.
12. Defer N, Best-Belpomme M, Hanoune J. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am J Physiol Renal Physiol 279: F400-F416, 2000.
13. Delmas P. Polycystins: from mechanosensation to gene regulation. Cell 118: 145-148, 2004.
14. Dessauer CW. Adenylyl cyclase-A-kinase anchoring protein complexes: the next dimension in cAMP signaling. Mol Pharmacol 76: 935-941, 2009
15. Devuyst O. The expression of water channels AQP1 and AQP2 in a large series of ADPKD kidneys. Nephron 78: 116-117, 1998.
16. Devuyst O, Wang X, Serra A. Vasopressin-2 receptor antagonists in autosomal dominant polycystic kidney disease: from man to mouse and back. Nephrol Dial Transplant 26: 2423-2425, 2011.
17. Fukuhara C, Liu C, Ivanova TN, Chan GC, Storm DR, Iuvone PM, Tosini G. Gating of the cAMP signaling cascade and melatonin synthesis by the circadian clock in mammalian retina. J Neurosci 24: 1803-1811, 2004
18. Gattone VH, Wang X 2nd, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9: 1323-1326, 2003.
19. 2+-calmodulin-dependent phosphodiesterase (PDE1): current perspectives. Cell Signal 17: 789-797, 2005.
20. Grantham JJ. Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach. Kidney Int 64: 1157-1162, 2003
21. Hanaoka K, Devuyst O, Schwiebert EM, Wilson PD, Guggino WB. A role for CFTR in human autosomal dominant polycystic kidney disease. Am J Physiol Cell Physiol 270: C389-C399, 1996.
22. Hanaoka K, Qian F, Boletta A, Bhunia AK, Piontek K, Tsiokas L, Sukhatme VP, Guggino WB, Germino GG. Co-assembly of polycystin-1 and-2 produces unique cation-permeable currents. Nature 408: 990-994, 2000.
23. Hanoune J, Defer N. Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 41: 145-174, 2001.
24. Hayashi M, Yamaji Y, Monkawa T, Yoshida T, Tsuganezawa H, Sasamura H, Kitajima W, Sasaki S, Ishibashi K, Maurmo F, Saruta T. Expression and localization of the water channels in human autosomal dominant polycystic kidney disease. Nephron 75: 321-326, 1997.
25. Helies-Toussaint C, Aarab L, Gasc JM, Verbavatz JM, Chabardes D. Cellular localization of type 5 and type 6 ACs in collecting duct and regulation of cAMP synthesis. Am J Physiol Renal Physiol 279: F185-F194, 2000.
26. Hoffert JD, Chou CL, Fenton RA, Knepper MA. Calmodulin is required for vasopressin-stimulated increase in cyclic AMP production in inner medullary collecting duct. J Biol Chem 280: 13624-13630, 2005.
27. Iyengar R. Molecular and functional diversity of mammalian Gs-stimulated adenylyl cyclases. FASEB J 7: 768-775, 1993.
28. Malbon CC, Tao J, Shumay E, Wang HY. AKAP (A-kinase anchoring protein) domains: beads of structure-function on the necklace of G-protein signalling. Biochem Soc Trans 32: 861-864, 2004.
29. Mangoo-Karim R, Uchic ME, Grant M, Shumate WA, Calvet JP, Park CH, Grantham JJ. Renal epithelial fluid secretion and cyst growth: the role of cyclic AMP. FASEB J 3: 2629-2632, 1989.
30. Michalski A, Grzeszczak W. [The effect of hypervolemia on electrolyte level and level of volume regulating hormones in patients with autosomal dominant polycystic kidney disease]. Pol Arch Med Wewn 96: 329-343, 1996
31. Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, Takahashi H, Wallace DP. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17: 2220-2227, 2006.
32. Nagao S, Nishii K, Yoshihara D, Kurahashi H, Nagaoka K, Yamashita T, Takahashi H, Yamaguchi T, Calvet JP, Wallace DP. Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat. Kidney Int 73: 269-277, 2008.
33. Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X, Elia AE, Lu W, Brown EM, Quinn SJ, Ingber DE, Zhou J. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 33: 129-137, 2003.
34. Nguyen AN, Jansson K, Sanchez G, Sharma M, Reif GA, Wallace DP, Blanco G. Ouabain activates the Na-ATPase signalosome to induce autosomal dominant polycystic kidney disease cell proliferation. Am J Physiol Renal Physiol 301: F897-F906, 2011.
35. Parfrey PS, Bear JC, Morgan J, Cramer BC, McManamon PJ, Gault MH, Churchill DN, Singh M, Hewitt R, Somlo S, Reeders ST. The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med 323: 1085-1090, 1990.
36. Patel TB, Du Z, Pierre S, Cartin L, Scholich K. Molecular biological approaches to unravel adenylyl cyclase signaling and function. Gene 269: 13-25, 2001.
37. Pierre S, Eschenhagen T, Geisslinger G, Scholich K. Capturing adenylyl cyclases as potential drug targets. Nat Rev Drug Discov 8: 321-335, 2009
38. Pinto C, Papa D, Hubner M, Mou TC, Lushington GH, Seifert R. Activation and inhibition of adenylyl cyclase isoforms by forskolin analogs. J Pharmacol Exp Ther 325: 27-36, 2008.
39. Pluznick JL, Zou DJ, Zhang X, Yan Q, Rodriguez-Gil DJ, Eisner C, Wells E, Greer CA, Wang T, Firestein S, Schnermann J, Caplan MJ. Functional expression of the olfactory signaling system in the kidney. Proc Natl Acad Sci USA 106: 2059-2064, 2009.
40. Portela-Gomes GM, Grimelius L, Johansson H, Efendic S, Wester K, Abdel-Halim SM. Increased expression of adenylyl cyclase isoforms in the adrenal gland of diabetic Goto-Kakizaki rat. Appl Immunohistochem Mol Morphol 10: 387-392, 2002.
41. -secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol 301: F1005-F1013, 2011.
42. Rieg T, Tang T, Murray F, Schroth J, Insel PA, Fenton RA, Hammond HK, Vallon V. Adenylate cyclase 6 determines cAMP formation and aquaporin-2 phosphorylation and trafficking in inner medulla. J Am Soc Nephrol 21: 2059-2068, 2010.
43. Roos KP, Strait KA, Raphael KL, Blount MA, Kohan DE. Collecting duct-specific knockout of adenylyl cyclase type VI causes a urinary concentration defect in mice. Am J Physiol Renal Physiol 302: F78-F84, 2012
44. Seamon KB, Padgett W, Daly JW. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci USA 78: 3363-3367, 1981.
45. Seifert R, Lushington GH, Mou TC, Gille A, Sprang SR. Inhibitors of membranous adenylyl cyclases. Trends Pharmacol Sci 33: 64-78. 2012.
46. Smith LA, Bukanov NO, Husson H, Russo RJ, Barry TC, Taylor AL, Beier DR, Ibraghimov-Beskrovnaya O. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol 17: 2821-2831, 2006.
47. Stangherlin A, Zaccolo M. Phosphodiesterases and subcellular compartmentalized cAMP signaling in the cardiovascular system. Am J Physiol Heart Circ Physiol 302: H379-H390, 2012.
48. Strait KA, Stricklett PK, Chapman M, Kohan DE. Characterization of vasopressin-responsive collecting duct adenylyl cyclases in the mouse. Am J Physiol Renal Physiol 298: F859-F867, 2010.
49. Sullivan LP, Wallace DP, Grantham JJ. Chloride and fluid secretion in polycystic kidney disease. J Am Soc Nephrol 9: 903-916, 1998.
50. Sunahara RK, Dessauer CW, Gilman AG. Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol 36: 461-480, 1996
51. Takaichi K, Kurokawa K. AVP-sensitive cAMP production is dependent on calmodulin in both MTAL and MCT. Am J Physiol Renal Fluid Electrolyte Physiol 255: F834-F840, 1988.
52. Tao J, Malbon CC. G-protein-coupled receptor-associated A-kinase anchoring proteins AKAP5 and AKAP12: differential signaling to MAPK and GPCR recycling. J Mol Signal 3: 19, 2008.
53. Thomson RB, Mentone S, Kim R, Earle K, Delpire E, Somlo S, Aronson PS. Histopathological analysis of renal cystic epithelia in the Pkd2WS25/-mouse model of ADPKD. Am J Physiol Renal Physiol 285: F870-F880, 2003.
54. Torres VE. Cyclic AMP, at the hub of the cystic cycle. Kidney Int 66: 1283-1285, 2004.
55. Torres VE. Therapies to slow polycystic kidney disease. Nephron Exp Nephrol 98: e1-e7, 2004.
56. Torres VE. Vasopressin antagonists in polycystic kidney disease. Semin Nephrol 28: 306-317, 2008.
57. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363-364, 2004.
58. 2+-permeable cation channel. J Biol Chem 276: 4093-4101, 2001.
59. Verani RR, Silva FG. Histogenesis of the renal cysts in adult (autosomal dominant) polycystic kidney disease: a histochemical study. Mod Pathol 1: 457-463, 1988.
60. Wallace DP. Cyclic AMP-mediated cyst expansion. Biochim Biophys Acta 1812: 1291-1300, 2011.
61. Wallace DP, Grantham JJ, Sullivan LP. Chloride and fluid secretion by cultured human polycystic kidney cells. Kidney Int 50: 1327-1336, 1996.
62. V-integrin receptor. Am J Physiol Renal Physiol 295: F1463-F1471, 2008.
63. Wang H, Storm DR. Calmodulin-regulated adenylyl cyclases: cross-talk and plasticity in the central nervous system. Mol Pharmacol 63: 463-468, 2003
64. Wang X, Ward CJ, Harris PC, Torres VE. Cyclic nucleotide signaling in polycystic kidney disease. Kidney Int 77: 129-140, 2010.
65. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 19: 102-108, 2008.
66. 2+ regulation of adenylyl cyclases in cAMP microdomains. Physiol Rev 87: 965-1010, 2007.
67. Wilson PD, Schrier RW, Breckon RD, Gabow PA. A new method for studying human polycystic kidney disease epithelia in culture. Kidney Int 30: 371-378, 1986.
68. Xu D, Isaacs C, Hall IP, Emala CW. Human airway smooth muscle expresses 7 isoforms of adenylyl cyclase: a dominant role for isoform V. Am J Physiol Lung Cell Mol Physiol 281: L832-L843, 2001.
69. Yamaguchi T, Hempson SJ, Reif GA, Hedge AM, Wallace DP. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 17: 178-187, 2006.
70. Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham JJ. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 30: 703-709, 1997.
71. Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63: 1983-1994, 2003.
72. Yamaguchi T, Pelling JC, Ramaswamy NT, Eppler JW, Wallace DP, Nagao S, Rome LA, Sullivan LP, Grantham JJ. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57: 1460-1471, 2000.
73. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growthstimulated phenotype. J Biol Chem 279: 40419-40430, 2004.
74. Yasuda G, Jeffries WB. Regulation of cAMP production in initial and terminal inner medullary collecting ducts. Kidney Int 54: 80-86, 1998.